DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Azacitidine adverse effects in patients with myelodysplastic syndromes.

Author(s): San Miguel Amigo L, Franco Osorio R, Mercadal Vilchez S, Martinez-Frances A

Affiliation(s): Department of Hematology, ICO-Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.

Publication date & source: 2011-06, Adv Ther., 28 Suppl 4:6-11. Epub 2011 May 12.

Publication type: Research Support, Non-U.S. Gov't; Review

Azacitidine is now considered one of the standard-of-care agents for patients with high-risk myelodysplastic syndromes who are not candidates for high-dose chemotherapy. Considering the mechanism of action of the agent, it is critical to maintain adequate dose intensities for prolonged periods of time in order for treatment to be effective. Therefore, aggressive prevention as well as treatment of side effects is critical. The drug mainly causes hematological toxicity that is managed with growth factor support, blood transfusions, and dose and schedule adjustment. Nonhematological side effects are mainly gastrointestinal and cutaneous in nature, and can be easily managed with symptomatic treatment and correct administration techniques.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017